Intercept Pharmaceuticals

NAS:ICPT

Pharmaceuticals: Other

Market Cap

$2.77bn

SMALL cap

Share Price ↑

$93.35 (1.65%)

YTD Return ↓

-4.0103%

since start of 2019

P/E Ratio

—

ICPT chart by TradingView

Source: FactSet financial data and analytics.

Corporate Values

Carbon Footprint
Pollution Prevention
Water Conservation
Data Privacy
Consumer Health
Employee Satisfaction
Workplace Safety
Corp Gov
Ethical Practices
Conflict Materials
Forced Labor
Gender Diversity

Legend

About

Pharmaceuticals: Other Founded 2002

Intercept Pharmaceuticals is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

website

Source: FactSet Research Systems

Headquarters

10 Hudson Yards

37th floor

New York, NY 10001

1.646.747.1000

Executives

Name	Title	Gender
David A. Shapiro, MD	Chief Medical Officer & Executive VP-Development	Male
Mark E. Pruzanski, MD	President, Chief Executive Officer & Director	Male
Paolo Fundar	Chairman	Male
Roberto Pellicciari, PhD	Founder	Male
Mark J. Vignola, PhD	Director-Investor Relations	Male
Sandip S. Kapadia, MBA, CPA	Chief Financial Officer	Male
Jerome B. Durso	Chief Operating Officer	Male

Mindful Investing Summary

Legend

Carbon Footprint — N/A

Intercept Pharmaceuticals among its competitors for its carbon footprint. A company’s performance in this category is based on its success in implementing energy efficiency measures. Investments in energy efficient technology, green building and sourcing of renewable energy can all lead to cost savings and reduce the company’s contribution to climate change.
Pollution Prevention — N/A

Intercept Pharmaceuticals on this issue. Companies are evaluated on pollution prevention by the levels of waste (including hazardous waste) they produce and release into the environment, and can be affected by whether they develop products that can reduce exposure to pollution.
Water Conservation — N/A

Intercept Pharmaceuticals among its peers in this category. A company’s score in this category depends on its measures to minimize water usage and impacts on stressed or drought-prone water resources.
Data & Privacy Protection — N/A

Intercept Pharmaceuticals among its peers and competitors for data privacy and protection. Companies today digitally manage vast amounts of personal information about their clients. A company’s score on this issue is based on the systems, products and procedures it has in place to minimize the risk for data and privacy breaches.
Consumer Health, Wellness & Safety — N/A

Intercept Pharmaceuticals compared to its peers and competitors Companies in this category manage its product and safety risks.
Employee Ownership, Satisfaction, Benefits & Pay — N/A

Intercept Pharmaceuticals among its peers for employee satisfaction and pay. A company’s score on this issue depends on its frequency and likelihood of labor disputes as well as its practices to keep and retain talent - such as compensation, family leave, employee health care and other benefits. Employers that are rated as good to work for consistently produce higher stock returns than their peers.
Workplace Health and Safety — N/A

Intercept Pharmaceuticals among its competitors on this issue. A company’s workplace health and safety is evaluated not only by the number of accidents and injuries in the workplace, but also by their safety policies, training procedures, and their investment in equipment that can reduce accidents.
Integrity of Corporate Governance — N/A

Intercept Pharmaceuticals among its competitors on corporate governance. This score is determined by the company’s accounting practices, executive pay, board organization and ownership structure.
Ethical Practices — N/A

Intercept Pharmaceuticals compared to its peers and competitors. A company’s rating on this issue is based on its history of controversies related to unethical corporate behavior, such as false claims about their products, price fixing, executive misconduct, insider trading or fraudulent practices.
Usage of Conflict Materials — N/A

Intercept Pharmaceuticals among its competitors in this category. Certain products use raw materials that are commonly sourced from militias or other organizations that promote or engage in conflict in their region. To perform well in this category companies must provide adequate assurances that any of these metals used in their production are in fact from conflict-free sources.
Forced Labor — N/A

Intercept Pharmaceuticals compared to its competitors on forced labor. A company’s score on this issue depends on its use of forced labor and on its work conditions for outsourced labor.
Diversity of Corporate Leadership 1 N/A

Intercept Pharmaceuticals performs very poorly based on its peers as well as companies in similar geographic regions. Companies are assessed on factors such as board diversity and senior management diversity. Companies performing well on this issue typically are more profitable than its peers, while companies with very poor scores typically have greater stock price volatility and lower returns on capital.

Intercept Pharmaceuticals - Competitors and Related Companies

How Intercept Pharmaceuticals stacks up to its peers in the Pharmaceuticals: Other industry or with competing business segments.